HC Wainwright & Co. Reiterates Buy on Allogene Therapeutics, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Allogene Therapeutics (NASDAQ:ALLO) and maintained a $10 price target on the stock.

March 19, 2024 | 10:55 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Robert Burns reiterated a Buy rating on Allogene Therapeutics and maintained a $10 price target.
The reiteration of a Buy rating and maintenance of a $10 price target by a reputable analyst firm like HC Wainwright & Co. typically signals a positive outlook on the stock, suggesting potential upside. This endorsement can positively influence investor sentiment and potentially lead to a short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100